Pre-Flush (Pre-Saturation) Validation Protocol

Document type	Protocol
Topic area	Drug Product
Level	Advanced
Updated	September 2026

This is a ready-to-use protocol for sizing and validating a pre-flush (pre-saturation) step ahead of final sterile filtration, so a filter’s finite membrane binding capacity is occupied before product filtration begins rather than depleting product concentration or a controlled excipient like polysorbate in the early filtrate. Replace every <<FILL: ...>> placeholder with your own specifics and route it through your normal document control, review, and approval. A worked filled specimen follows. Verify each cited reference against the current source before you rely on it.

Document control header

Field	Entry
Document title	Pre-Flush Validation Protocol for `<<FILL: product / filter>>`
Document number	`<<FILL: e.g. PF-2026-01>>`
Version	`<<FILL>>`
Effective date	`<<FILL>>`
Filter model / membrane chemistry	`<<FILL>>`
Protocol owner	`<<FILL: e.g. Validation Lead>>`

1. Purpose

This protocol defines the study used to size and validate a pre-flush volume for <<FILL: filter model>> ahead of <<FILL: product>> filtration, confirming pre- and post-filtration concentration and any controlled excipient match the product’s own specification.

2. Scope

Dimension	Decision
Product / formulation	`<<FILL>>`
Protein/API concentration	`<<FILL>>`
Controlled excipient at risk (e.g. polysorbate 20/80)	`<<FILL>>`
Out of scope	`<<FILL: e.g. bacterial retention, validated separately>>`

3. Responsibilities

Role	Responsibility
Sponsor validation lead	Designs and owns the pre-flush sizing study.
Formulation / process development	Confirms which components (protein, polysorbate) are at risk of adsorption for this specific formulation.
Manufacturing	Executes the validated pre-flush at the sized volume in routine batches.
Quality Assurance	Approves the protocol and the validated pre-flush volume.

4. Prerequisites

Prerequisite	Status
Filter material compatibility and adsorption risk assessed (see the paired Filter Material Compatibility and Adsorption Risk Assessment)	`<<FILL>>`
Analytical method available to measure the at-risk component (protein concentration, polysorbate assay) at the sensitivity needed	`<<FILL>>`
Representative placebo or surrogate fluid available, so drug substance is not consumed by the sizing study itself	`<<FILL>>`

5. Study design

Field	Entry
Fluid used	`<<FILL: representative placebo, not active drug product>>`
Throughput points sampled	`<<FILL: e.g. a series of volumes expressed as L/m2 of filter area>>`
Components measured at each point	`<<FILL: protein concentration, polysorbate content>>`
Comparator	Steady-state sample taken later in a full-length run

6. Acceptance criteria

Criterion	Requirement
Depletion resolves within the tested throughput range	The point where concentration returns to within specification is identified with margin
Validated pre-flush volume set with margin	Set above the point where depletion resolves, not at the boundary
No unexplained protein loss at any point tested	Any measurable loss is traced to adsorption and addressed, not left unexplained

7. Batch record specification

State explicitly in the routine batch record: the exact pre-flush volume, the fluid used for the flush, and the point in the process sequence where in-process product sampling begins, so the depleted early filtrate never reaches the fill line unaccounted for.

8. Deviation handling

A pre-flush volume executed short of the validated volume, or a flush fluid substitution, is a deviation requiring an impact assessment on the batch’s protein concentration and controlled excipient content before disposition.

9. Summary and conclusion

State the validated pre-flush volume, the fluid used, and confirm it is the volume released into the routine batch record.

10. References

PDA Technical Report No. 26, Sterilizing Filtration of Liquids. Published comparisons of membrane adsorption behavior (PES, PVDF, nylon) for protein and polysorbate.

Confirm the current version of each reference before issue.

11. Revision history

Version	Date	Author	Summary of change
`<<FILL: 1.0>>`	`<<FILL>>`	`<<FILL>>`	Initial issue.

12. Approvals

Role	Name	Signature	Date
Author (Validation lead)	`<<FILL>>`
Reviewer (Formulation/Process Dev)	`<<FILL>>`
Approver (QA)	`<<FILL>>`

Filled specimen

Extract for an example low-concentration antibody final filtration step. Company, product, and numbers are illustrative.

Field	Entry
Product / formulation	Acme Therapeutics, monoclonal antibody at 5 mg/mL with polysorbate 80 at 0.02% w/v
Filter	0.2 micron hydrophilic PVDF
Throughput points sampled	0, 2, 4, 6, 8, 10 L/m2
Result	Measurable polysorbate depletion through 4 L/m2; concentration returned to within specification by 6 L/m2; no significant protein loss detected at any point
Validated pre-flush volume	8 L/m2, set with margin above the 6 L/m2 resolution point
Batch record specification	Pre-flush executed with representative placebo, 8 L/m2, discarded to waste; in-process product sampling begins immediately after the flush completes

Common inspection findings this protocol prevents

A filter selected on flow performance alone, with no adsorption or pre-flush study behind it.
A pre-flush volume chosen arbitrarily with no throughput study showing where depletion resolves.
A pre-flush executed with active drug product rather than a representative placebo, wasting drug substance.
A batch record with no stated pre-flush volume or sampling start point, leaving depleted early filtrate unaccounted for.

How to adapt this protocol

Set your document number, filter, and formulation in the header.
Confirm which components are actually at adsorption risk for this specific formulation before designing the study.
Run the sizing study on a representative placebo, not active drug substance.
Set the validated volume with real margin above the point where depletion resolves, and write it explicitly into the batch record.